Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Texas House Bill 3703: What You Need to Know

The state of Texas has been in the news in recent months as the legislature review House Bill 3703. This bill relates to “the prescription of low-THC cannabis for medical use by certain qualified physicians to patients with [specific] qualifying conditions”. Originally filed in March of 2019, this bill made its way through the house…
Read More →

Research shows cannabis can lower opioid dosage, but studies are preliminary

Larson cited one statistic to justify his bill: “Studies have shown up to 75% reduction in opioid dosage for medical cannabis users” The intersection of medical cannabis and opioid use as treatments for chronic pain is an emerging field of research as more states loosen regulations on medical and recreational use of marijuana. But does…
Read More →

European Parliament Passes Cannabis Resolution, Joins WHO In Supporting Medical Marijuana

Following reports about the World Health Organization (WHO) recommending a rescheduling of cannabis and several of its key components under international drug treaties, the European Parliament voted on Wednesday on a resolution that would help advance medical cannabis in the countries that form the European Union. Read the full story here.
Read More →

Updated Arfinn Med Scheduler

As your practice begins to grow, it’s important that your booking system is able to keep up.  That’s why Arfinn Med has just released, in its newest update, the multi-view scheduling and booking platform.  This allows you and/or your staff the ability to customize appointment types, hours of availability, display name, and confirmation emails for…
Read More →

Alternative Mississippi medical marijuana program barely wins approval from Senate

JACKSON • Legislation that would create a new medical marijuana program in Mississippi if the voter-approved Initiative 65 is overturned in court cleared the state Senate on the second try last week early on Friday morning. Senate Bill 2765, the Mississippi Medical Cannabis Act, failed by a single vote Thursday evening. But six hours later, after…
Read More →

CEO Spotlight: James West

As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More →

Leave a Comment

You must be logged in to post a comment.